A 15-Second Listen That Could Save Your Life

Mayo Clinic and Eko Health's AI stethoscope detects heart failure 2x faster, transforming US primary cardiac care

15 May 2026

Some 6.5 million Americans live with heart failure. Many do not know it. The condition often goes undetected in primary care, where the tools to confirm a diagnosis have long been out of reach: echocardiograms require specialists and equipment that most clinics, especially rural ones, do not have. A stethoscope, by contrast, fits in a pocket.

Now that humble instrument has been given a sharper ear. A collaboration between Mayo Clinic and Eko Health has produced a digital stethoscope that captures both heart sounds and ECG data, then runs them through an algorithm trained on more than 100,000 patient recordings. The device, cleared by the FDA and validated in over 70 published studies, can flag likely heart failure in under 15 seconds.

The results, highlighted by the American Hospital Association in May 2026, are striking. In a study tracking nearly 1,000 primary care clinicians over 12 months, those using the AI-enabled device detected 2.3 times more heart failure cases than peers with standard equipment. In a separate trial of nearly 1,200 pregnant women, the tool identified peripartum cardiomyopathy, a leading cause of maternal death in the United States, at twice the rate of standard screening. Because the condition closely mimics the ordinary discomforts of pregnancy, it is routinely missed until it is not easily treated.

The technology's promise is clearest at the margins of the system. Community health centres and rural clinics, which have never had access to specialist-grade cardiac diagnostics, can now, in theory, offer something close. That is not a trivial shift. Most cardiac disease is first encountered in primary care and most often missed there.

Caveats apply. Researchers note a risk of false positives, which could push patients toward unnecessary and costly follow-up tests. Validation across more diverse patient populations is still ongoing. And the word "theory" above does real work: a device's existence does not guarantee its adoption, its funding, or its equitable distribution across a fragmented health system.

Still, the direction of travel is notable. For decades, early cardiac detection has depended on access to expensive infrastructure. A 15-second screening tool that fits in a coat pocket does not solve that problem. But it does, for the first time, make the problem smaller.